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EFFECT OF COLD ISCHEMIA TIME ON THE EARLY OUTCOME 
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Five hundred ninety-three cadaveric livers were used 
for primary liver transplantation between October 24, 
1987, and May 19, 1989. The grafts were procured with 
a combined method, using in situ cooling with cold elec-
trolyte solution and backtable flushing with UW solu-
tion. The mean cold-ischemia time was 12.8 (range 2.4-
34.7) hr. The cases were divided into 5 groups according 
to the cold-ischemia time: group 1: <10 hr (n=223); 
group 2: 10-14 hr (n=188): group 3: 15-19 hr (n=101); 
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group 4: 20-24 hr (n=52); and group 5: ~OR hr (n=29). 
There was no difference between the 5 groups in I-year 
patient survival, highest SGOT in first week after op-
eration, and SGOT and total bilirubin during the first 
month after operation. However, with a logistic regres-
sion model, the retransplantation rate (P=O.OOI) and 
primary nonfunction rate (P=0.006) significantly rose 
as cold-ischemia time increased, meaning that the equiv-
alency of patient survival was increasingly dependent 
on aggressive retransplantation. 
The development of the University of Wisconsin solution 
was announced by Jamieson et a1. (1) at an international 
transplantation conference held in Pittsburgh in September 
1987 (1). The Madison group already had evaluated the solution 
for liver transplantation in dogs and had acquired an early 
clinical experience (1, 2). Within less than a month, we were 
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manufacturing our own supply and were using the solution 
clinically (3), having confirmed the Wisconsin claims in ani-
mals (4). By the spring of 1988, the magnitude of the advance 
was generally appreciated. Since then, the superiority of the 
University of Wisconsin solution to the previously used Euro-
Collins solution has been so overwhelmingly confirmed that 
the citation of selected trials is an inequity to many more. In 
contrast to maximum limit of 6 or 8 hr with EC solution, all 
centers have been able to relax their storage-time restrictions. 
In various reports, the mean and range of cold-ischemia times 
have been 12.6 (2-24) hr in Wisconsin (5); 11.5 (3-20) in Los 
Angeles (6); and 7.23 (range not given) in Dallas (7). In our 
center, mean cold-ischemia time with UW preservation has 
been 12.8 (2.4-34.7) hr. 
In spite of our enthusiasm about the UW solution, we have 
presented evidence that deterioration of preserved canine livers 
is substantial by 24 hr (4). However, there has been no pub-
lished evidence that human liver transplantation results are 
adversely affected by increasing the cold-ischemia time. There-
fore, we looked at this question in 593 patients who underwent 
primary transplantation between October 24, 1987, and May 
19,1989. 
MATERIALS AND METHODS 
Recipient case material. Six hundred twenty-four patients had liver 
transplantation for the first time using liver grafts that were preserved 
with UW solution. Thirty-one of these cases were excluded because of 
insufficient data. The remaining 593 patients were followed until June 
1990, allowing 13-32-month periods of posttransplant observation; 93 
(15.7%) were infants or children «18 years), and 500 (84.3%) were 
adults (Table 1). The ages ranged from newborn to 73.8 years, older 
recipients being significantly more frequently represented in group 4. 
Other features are summarized in Table 1. Almost 5% of the recipients 
had antidonor antibodies, either with positive cytotoxic crossmatches 
or ABO incompatibilities. Many were critically ill as reflected by UNOS 
4 or UNO-stat classification, meaning that these patients were rcu 
bound and usually on ventilators. 
During the 13-32-month follow-up, 105 (17.7%) of the starting group 
underwent retransplantation, and in 57 (9.6%), the retransplantation 
was within 14 days. The reasons for retransplantation were classified 
from clinical and pathologic findings as the following: I, technical; 2, 
rejection; 3, primary non function; 4, infection; and 5, miscellaneous. A 
diagnosis of primary nonfunction was made if a graft never demon-
strated evidence of initial function following transplantation. Clinical 
findings and examinations strongly associated with primary nonfunc-
tion included stage 4 coma, uncorrectable coagulopathy, renal failure, 
cardiodynamic shock, acidosis, and profound hypoglycemia. The pa-
thology of such grafts invariably showed massive ischemic necrosis 
without evidence of rejection. 
Donor case material. The 593 donors were newborn to 58 years old. 
Their length of hospitalization, cardiopulmonary function, and hepatic 
status are summarized in Table 2. One donor whose total bilirubin was 
18 mg% died during a sickle cell crisis; the transplanted liver functioned 
well. Low mean arterial pressures were common, and 2 livers were 
TABLE 1. Features of 593 recipients of primary liver grafts and their numbers in the various cold-ischemia time (CIT) groups 
Group 1 Group 2 Group 3 Group 4 Group 5 
CIT (hr) <10 10-14.9 15-19.9 20-24.9 ;;.25 
n 223 188 101 52 29 
Age (years) 38.3 38.3 40.7 45.5a 45.0 
Sex (m/f ratio) 1.3 1.4 1.7 1.1 0.8 
UNOS score 4 or UNOSTAT 79 (35.4%) 72 (38.2%) 30 (29.7%) 13 (25.0%) 6 (20.7%) 
Crossmatch positive 12 (5.4%) 8 (4.3%) 3 (3.0%) 0(0.0%) 1 (3.4%) 
Blood type mismatch 3(1.3%) 2 (1.1%) 1(1.0%) 0(0.0%) 0(0.0%) 
a P<0.5 vs. group I, group 2; the older age in this CIT group was the only significant difference between groups in any of the parameters. 
TABLE 2. Features of the donors in the various cold-ischemia time (CIT) groups 
Group 1 Group 2 Group 3 Group 4 Group 5 
Demographics 
CIT (hr) <10 10-14.9 15-19.9 20-24.9 ;;.25 
n 223 188 101 52 29 
Age (years) 22.9 23.0 23.5 24.1 20.9 
Sex (M/F ratio) 1.9 2.2 1.8 1.8 2.5 
Hospital stay (days) 3.0 5.6 3.2 4.1 2.4 
Liver functions 
T. BIL (mg/ell) 0.96 1.72 1.23 0.91 0.91 
SGOT (u/L) 87.7 84.3 78.6 76.9 63.6 
SGPT (u/L) 49.5 52.8 47.2 52.3 47.1 
PT (sec) 13.7 13.9 13.4 14.1 14.5 
Cardio/pulmonary functions 
P02 (mmHg) 146.3 154.7 154.7 158.4 205.3 
PC02 (mmHg) 32.9 30.3 30.1 29.8 31.8 
PH 7.39 7.42 7.39 7.44 7.42 
Lowest blood pressure (mmHg) 80.0 82.0 77.9 81.6 79.1 
Solution 
Electrolyte (ml)a 7175 7130 7427 7813 7815 
UW (ml)b 1874 2187 2097 2082 2441 
a Used for in situ cooling. 
b Used for backtable flushing and priming of preservation bag. 
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removed after the donors had cardiac arrest. The most common causes 
of death were motor-vehicle accidents, gunshot wounds, and cerebro-
vascular accidents in that order. More than half the livers were procured 
with kidneys and hearts. The foregoing donor factors were evenly 
distributed in livers with short, intermediate, and long cold-ischemia 
times (CIT), with no statistically significant differences (Table 2). 
Donor hepatectomy was performed by standard techniques as part 
of multiple organ procurements (8) or with a modified rapid-flush 
method (9) for unstable donors. All procurements wee made before 
UW solution was commercially available, and during the first 4 months 
the solution was prepared in the School of Pharmacy of the University 
of Pittsburgh from raw materials bought from chemical suppliers. After 
this, it was supplied by the Department of Medical Research, DuPont 
Corporation, 1600 Waukegan Road, Waukegan, IL 60085. Throughout 
the period of case acquisition, the UW solution was a scarce resource 
worldwide and subject to rationing. In addition, host procurement 
teams at first were suspicious of the solution and usually would not 
permit its intraaortic infusion into the kidneys. For these reasons, a 
"mixed" technique was used in which core aortic cooling was with 
lactated Ringer's or a Collins solution according to the host-team 
instructions. The procurements were with standard surgical technique. 
The amounts used are recorded in Table 2. The liver was secondarily 
perfused 0" t he back table with UW solution, primarily through the 
portal vein, but sometimes with an additional arterial flush. In retriev-
ing data, the total UW solution use was recorded (Table 2) that included 
about 500 ml instilled into the preservation bag. The volumes were 
smaller in pediatric donors. 
Recipient care. Recipient hepatectomy and hepatic replacement were 
performed by standard techniques (10). Before revascularizing the new 
liver, the organ was perfused with 300-500 mllactated Ringer's solution 
or in a few cases plasmanate to remove air and excess potassium. 
Postoperative immunosuppression was with cyclosporine and low-dose 
steroids, with supplementary monoclonal antilymphocyte globulin 
(OKT3) and/or azathioprine as indicated (10). 
Data analysis. All evaluation parameters were in the recipient, and 
included patient and graft survival, graft function, and the frequency 
of retransplantation. Stratification was into 5 groups defined arbitrarily 
by the cold-ischemia time (CIT) as follows: group 1: <10 hr (n=223); 
group 2: 10-14 hr (n=188); group 3: 15-19 hr (n=101); group 4: 20-24 
hr (n=52); and group 5: ;::25 hr (n=29). The exact CIT distribution to 
the nearest hour is shown in Figure 1. 
Statistical evaluation of the results was by chi-square test, analysis 
of variance, simple regression analysis, and logistic regression analysis. 
RESULTS 
Patient and graft survival. Over all, patient survival was 
77.2% at the end of 1 year (Fig. 2). There was no difference in 
patient survival between the different CIT groups. However, 
there were differences in early graft survival (Fig. 3). At various 
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FIGURE 1. Distribution of cold-ischemia time (CIT). 
time points within the first few weeks, the need for retrans-
plantation in groups 4 and 5 (especially group 4) was signifi-
cantly greater (Fig. 3). Thus, the equivalence of eventual patient 
survival shown in Figure 2 was dependent on aggressive retrans-
plantation. 
Retranspiantation. The incidence and reasons for retrans-
plantation during the first 14 postoperative days are summa-
rized in Figure 4. When the CIT was less than 10 hr, the 
retransplantation rate was 5.4%, whereas it was double, triple, 
or quadruple this rate with successively longer preservation 
times. Primary nonfunction was the principal course of graft 
loss during the first 2 weeks no matter what the CIT, and 
rejection was the least important factor (Fig. 4). The increase 
in retransplantation in groups 4 and 5 versus groups 1-3 was 
significant (see significance notations in Fig. 4). The trend to 
a higher retransplantation rate with longer preservation using 
the logistic regression model was unmistakable and significant 
(P<O.OOI) throughout the entire spectrum of preservation time 
(Fig. 5). The dominant contribution of primary non function to 
retransplantation need was also evident (Fig. 5). The increased 
incidence of rejection with increased CIT (Fig. 4) was notewor-
thy but not significant. 
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FIGURE 2. Recipient patient survival according to CIT. Actual 
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using a logistic regression model. 
Liver function tests. The duration of CIT was not reflected 
in the SGOT and serum bilirubin values that are summarized 
in Figures 6 and 7 up to 1 month for all primary grafts that 
remained in place for this long. In all the groups, the original 
sample sizes were reduced with the passage of time, since data 
entry ceased when grafts were lost by death or retransplanta-
tion. The early postoperative culling process was more exten-
sive with each increment of ischemia time because larger num-
bers of dysfunctional grafts were replaced (Figs. 4 and 5). The 
livers that remained had similar average SGOT (Fig. 6) and 
serum bilirubin values (Fig. 7). However, even when all cases 
were recorded during the first 7 days, there was no correlation 
between CIT and the highest SGOT values (Fig. 8). 
DISCUSSION 
The improved preservation made possible by the UW solu-
tion has revolutionized the field of liver transplantation (1-3). 
Long-distance procurement, organ sharing, back-table evalua-
tion and reconstruction including size reduction, and more 
complete preoperative and intraoperative recipient preparation 
have all become feasible. In addition, the incidence of primary 
graft nonfunction and thrombosis of the graft vessels were 
reduced (3), However, the results herein reported caution 
against undue procrastination in the use of these livers. A 
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FIGURE 8. Highest SGOT values during the first 7 days after trans-
plantation of all 593 grafts and the relation of these figures to CIT. 
There was no correlation. 
statistically definable price could be identified that was cumu-
lative with time but that often was not evident in individual 
cases. Most of the organs preserved for 20 hr or more were 
satisfactory, attesting the efficiency of the method used, but 
the necessity for life-saving retransplantation because of pri-
mary graft nonfunction or other reasons became progressively 
more frequent. The effective use of retransplantation prevented 
a commensurate increase in mortality. 
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It was reassuring that success often was possible beyond 20 
hr. After our longest preservation (>34 hr), the result was 
perfect. However, planned acceptance of an extra risk is not 
justifiable. Our present policy is to make every attempt to 
revascularize liver grafts within 20 hr since the early graft 
failure rate was increasingly nonlinear beyond this time. 
Although the folly of complete indifference to CIT is evident, 
the time constraints delineated in this study may understate 
the value of UW because of the conditions of testing (11). The 
potentially suboptimal policy was in effect throughout the study 
of preliminary flushing with electrolyte solutions. Since com-
pletion of this study, we have used the now freely available UW 
solution as the sole infusate from the outset. This is the policy 
recommended by Belzer (11). However, the trend in the new 
cases is similar to that in the earlier experience. 
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